The phenylketonuria mouse model: a meeting review
|
|
- Nathaniel Lambert
- 5 years ago
- Views:
Transcription
1 Molecular Genetics and Metabolism 76 (2002) Review The phenylketonuria mouse model: a meeting review J. David McDonald, a, * Maria Andriolo, b Francesco Calı, b Mario Mirisola, c Stefano Puglisi-Allegra, d Valentino Romano, c Christineh N. Sarkissian, e and Carolyn B. Smith f a Department of Biological Sciences, Wichita State University, Wichita, Kansas, USA b OASI Istituto per la ricerca sul ritardo mentale e l involuzione cerebrale, Troina, Sicily, Italy c Department of Biopathology and Biomedical Methodology, University of Palermo, Palermo, Sicily, Italy d Department of Psychology, University of Rome, and Fondazione Santa Lucia IRCCS, Rome, Italy e McGill University Montreal Children s Hospital Research Institute, Montreal, Que., Canada f Laboratory of Cerebral Metabolism, National Institute of Mental Health, Bethesda, MD, USA Received 20 May 2002; received in revised form 6 June 2002; accepted 6 June * Corresponding author. Fax: address: david.mcdonald@wichita.edu (J. David McDonald). The BTBR-Pah enu2 PKU mouse line has been characterized to a degree that enables its use as a reliable model for human phenylketonuria (PKU). Numerous studies documenting the genetics, biochemistry, and phenotype of this PKU mouse strain have demonstrated striking similarities to the human disease. Recently, a meeting was held in Troina, Sicily entitled Mouse Models in Phenylketonuria Research. The presentations at this meeting were descriptions of the usage of this disease model to investigate different aspects of the PKU syndrome, to reveal previously unknown aspects of the molecular etiology of PKU, and to explore new treatment regimens. The meeting concluded with a roundtable discussion with the intent to articulate issues arising from current research with the mouse PKU model and to point to potentially fruitful areas for future research. It is hoped that the proceedings of this meeting will provide the interested reader both with an overview of most of the current scientific projects and an enhanced understanding of the experimental possibilities afforded by this very accurate disease model. For the purpose of this article, a brief summary of each presentation will be made, including a statement of specific issues raised and suggestions for certain future experimental directions stemming from the experimental results. The article will then conclude with a broader statement of current research, troubling issues, and future directions that arose during the roundtable discussion. Dr. J. David McDonald of Wichita State University opened up the meeting with a description of his research to characterize the modeling of the maternal PKU syndrome displayed by this mouse strain [1]. He described how a defined diet deficient in phenylalanine (Phe), used in conjunction with different levels of Phe in the drinking water, allowed the manipulation of the blood Phe levels of pregnant PKU females. This dietary manipulation can be used to produce maternal blood Phe levels, emblematic of any of the three classes of dietary treatment of classical PKU: untreated (highly elevated blood Phe), treated (normal blood Phe), or partially treated (elevated blood Phe). With this system, he was able to show with very high statistical significance that three fetal morphometric parameters (i.e., head circumference, body weight, and body length) were all reduced in the offspring of PKU females with elevated blood Phe levels during pregnancy compared to those offspring of PKU females with normal blood Phe levels. Because these morphometric parameters are likewise affected in human maternal PKU, this result serves to verify that this model, already known to model the neonatal aspects of PKU, also models the maternal PKU syndrome. Further, the defined diet should permit a more thorough investigation of the relationship between maternal blood Phe and fetal birth defects. In this study, both test and control pregnancies were set up to produce litters composed of half-mutant and half-nonmutant fetuses. A direct PCR-based genotyping assay was used to identify the genetic status of each fetus /02/$ - see front matter Ó 2002 Elsevier Science (USA). All rights reserved. PII: S (02)
2 J. David McDonald et al. / Molecular Genetics and Metabolism 76 (2002) so that the question could be asked as to whether either class was more severely affected [2]. The results showed that, in this mouse model system as in the human disease, fetal genotype does not appear to be a significant factor in teratology. In both systems, the important factors are maternal genotype and maternal diet. Another aspect of the maternal PKU syndrome that this research revealed to be similar between mice and humans is the approximately twofold Phe concentration gradient across the placental barrier into the fetal compartment. Both in mice and humans, this concentration gradient amplifies the exposure of the developing fetus to blood Phe and, in doing so, is likely to exacerbate the metabolic imbalance of PKU by interfering with the transport of other metabolites that use the same transport protein at the placental barrier. An especially compelling question that arises from this line of research is the extent and the types of birth defects that arise as a result of switching maternal blood Phe levels during pregnancy. Although switching from elevated to normal and from normal to elevated would be of interest, the former type of switch is likely to be of greatest immediate biomedical interest because it mimics the common occurrence in human maternal PKU pregnancies in which the PKU female is already several months into a pregnancy before dietary treatment has begun. Other pressing issues that can be addressed with this maternal PKU modeling system is the intensive investigation of the biochemical, molecular, and cellular bases of the damage to the brains and hearts of fetuses gestated in a maternal PKU uterus [3]. Dr. Stefano Puglisi-Allegra from the University of Rome presented results from his studies into two aspects of the BTBR-Pah enu2 model: neurochemistry and cognitive deficits. With regard to the neurochemistry, his studies revealed dramatic deficits in the concentration of brain neurotransmitters in mutant versus nonmutant animals [4]. In all, six areas of mouse brain (prefrontal cortex, cingulate cortex, hippocampus, amygdala, nucleus accumbens, and caudatus putamen) were assessed for both catecholamine (norepinephrine and dopamine) and indolamine (serotonin) neurotransmitter levels. All six areas of the mouse brain were shown to have very notable deficits of serotonin levels. Two areas of brain, the cingulate cortex and the hippocampus, also showed dramatic decreases in norepinephrine and dopamine. However, catecholamine decreases were less striking in other brain areas. In seeking a mechanism for the general reduction in neurotransmitter levels, they found several possible factors that may be responsible and warrant further investigation. For example, measuring brain levels of the large neutral amino acids tyrosine (Tyr) and tryptophan (Trp), the respective precursors of catecholamine and indolamine neurotransmitters, showed that they were reduced. This suggests that their reduction leads to the observed neurotransmitter reduction. However, these researchers also noted that the reduction in brain Trp levels was not severe and they made another observation that suggests a different reason for the observed reduction. They noted that, while brain levels of Trp were modestly reduced, the levels of 5-hydroxytryptophan, the next intermediate after Trp on the pathway to serotonin, were very dramatically reduced. They interpreted these results to suggest that the serotonin deficit is due to the inhibition of the enzyme Trp hydroxylase by high brain Phe levels. They speculated further that a similar inhibitory action may be contributing to the reduction in catecholamine neurotransmitters, since Tyr hydroxylase and Trp hydroxylase are very similar enzymes, comprising (with Phe hydroxylase) a family of aromatic amino acid hydroxylases, encoded by genes related through common descent. To assess cognitive ability, Dr. Puglisi-Allegra and his colleagues sought out tests that would not use explicit (positive or negative) reinforcement and would avoid the effects of a lengthy training component and thus provide analogous tests of recognition given to human subjects. They elected to use two non-associative tasks: the Spatial Novelty Test (SNT) and the Object Recognition Test (ORT). These two tests take advantage of the spontaneous preference that rodents display for novel stimuli. In SNT, animals are expected to explore objects that have been displaced from a previous position [5]. In ORT, animals are expected to explore a novel object that is similar to a previously explored sample [6]. The SNT is designed to estimate the ability of rodents to encode spatial relationships while ORT has been developed as a variant of the delayed non-matching to sample tasks. The homozygous PKU mutants failed both tests by exhibiting very poor processing of spatial and non-spatial information compared to their nonmutant siblings. These observations support the view that cognitive deficits promoted by hyperphenylalaninemia might depend on neurodevelopmental disturbances involving late developing brain structures. Dr. Carolyn Smith from NIMH presented research in which she compared the rates of cerebral protein synthesis in adult PKU mutant and nonmutant animals and found a 20% reduction in the average cerebral protein synthesis rate [7]. Her investigations also revealed that the high levels of arterial Phe in mutant animals produce an elevated level of brain Phe and also lead to significant reductions in the brain levels of other large neutral amino acids (viz., tyrosine, tryptophan, leucine, isoleucine, histidine, methionine, threonine, and valine). It has long been speculated that a reduced rate of protein synthesis in brain is a major etiological factor in the development of mental retardation in untreated PKU. The decrease in protein synthesis is thought to be the simple and direct result of the reduction in the influx of
3 258 J. David McDonald et al. / Molecular Genetics and Metabolism 76 (2002) large neutral amino acids. Dr. Smith s results suggest that the situation is actually more complex and that the relationship of the reduction in protein synthesis to the neuropathology of PKU is still unclear. Her results suggest that the brain compensates for a reduction in the influx of large neutral amino acids with amino acids liberated from intracerebral protein pools. Thus, although she found a 20% reduction in the intracerebral level of leucine, there was no significant reduction in the concentration of leucine bound to trna. Further, experimental results indicated that in the mutant mice most of the leucine bound to trna was derived from protein degradation within the brain; in the nonmutant animals, the fraction from protein degradation was less than half. Thus, while this research confirms a long-held belief about the effect of the PKU metabolic imbalance on brain metabolite levels and protein synthesis rates, it forces a reexamination of the precise role that these events play in the molecular basis of the neuropathology associated with untreated PKU. These results clearly indicate that in the adult brain amino acids derived from protein degradation may provide a buffer against limitations in amino acid transport at the blood brain barrier. These findings suggest a number of future experiments, aimed at revealing the precise relationship between the metabolic imbalance of PKU and the neuropathology that follows from this imbalance. Does the compensation provided by protein degradation come with a cost to the tissue or does it merely represent a shifting of existing tissue pools? Are particular proteins targeted for degradation to produce amino acids or is this a more global phenomenon within the central nervous system? Another important area of research is the further understanding of the decreased rate of protein synthesis. Is there a particular factor or step in the process that is governing the change or is the effect on protein synthesis secondary to other cellular changes? The question of the reversibility of the observed effect merits study. If proteins are degraded to overcome a reduction in amino acid influx, are those proteins replaced when the metabolic imbalance is relieved? This is an important question because, while the brain is in many respects an organ that demonstrates compensation, it is well established that brain damage incurred in untreated PKU is irreversible. Among other questions, it will likely be very important to use the model to identify the presence of especially sensitive developmental windows and to examine the dose response relationship within those windows. It is likely that such studies will lead to a greater understanding of the molecular etiology of mental retardation in PKU and it is hoped that this will help reduce the incidence of this pathological feature of the disease. Dr. Valentino Romano and his colleagues Drs. Mario Mirisola, Maria Andriolo, and Francesco Calı from the University of Palermo and OASI Instituto per la ricerca sul ritardo mentale e l involuzione cerebrale in Sicily presented proteome research in which the protein expression profiles, obtained by two-dimensional protein electrophoresis and digital imaging [8,9], from the brains of age- and sex-matched mutant and nonmutant animals were compared. These maps display striking differences in the type, number, and levels of expressed genes between these two classes. Dr. Romano found about 30% similarity between the two proteome profiles, while the differences that were revealed fell into both of the two possible classes: (1) proteins present in the PKU mice but not in the nonmutant animals and (2) proteins present in the nonmutant animals but not in the PKU mice. Their first round of analysis focused on the first group of proteins. They compared the bi-dimensional gel mobility of the proteins with that of other known proteins for similarity. So far in this analysis, a number of proteins show no similarity to known proteins for these two parameters. However, there are proteins within this group that share apparent molecular weight and isoelectric point with specific proteins known to play a role in other neurodegenerative pathologies such as Down s syndrome and senile dementia. Dr. Romano s group seeks to extend the analysis of the proteins showing differences between mutant and nonmutant classes through protein sequencing and comparison with protein sequence in the SWISSPROT database. Dr. Romano s group also reported the discovery of a specific Phe hydroxylase mrna in adult mouse brain (manuscript in preparation). Phe hydroxylase is encoded by a single gene in both mouse and human. The enzyme converts Phe to Tyr by a hydroxylation reaction. The expression of the Phe hydroxylase gene has been demonstrated in human and mouse liver and, to a lesser extent, in mouse and human kidneys. The presence of Phe hydroxylase activity in the brain tissue of both species has been hypothesized but never demonstrated [10,11]. The level of this newly discovered transcript in brain tissue is comparable to liver tissue as judged by Northern blot analysis. However, no Phe hydroxylase activity can be detected in whole brain crude extract by using the 14 C-Phe-hydroxylation assay. Furthermore, they were unable to detect Phe hydroxylase protein in crude brain extracts by Western blot analysis with monoclonal antibody directed at Phe hydroxylase. To explain the apparent discrepancy between RNA and protein data, they analyzed Phe hydroxylase mrna from both tissues. That analysis revealed a significant modification in the brain Phe hydroxylase transcript. The discovery of a Phe hydroxylase transcript that does not appear to be expressed in adult brain opens the possibility that Phe hydroxylase may be ex-
4 J. David McDonald et al. / Molecular Genetics and Metabolism 76 (2002) pressed at some other time during the development of the mouse brain. Further analysis will be undertaken to examine earlier developmental stages for the presence of Phe hydroxylase protein. Dr. Christineh Sarkissian of McGill University presented research results describing the use of the mouse PKU models to evaluate the efficacy of oral enzyme substitution therapy with Phe Ammonia Lyase (PAL) as adjunct alternative therapy for PKU, independent of artificial diets. She also described ways in which she and her colleagues have mimicked various degrees of hyperphenylalaninemia. They have controlled Phe levels in BTBR-Pah enu2 homozygotes to model reproducible euphenylalaninemia and predictable untreated classical PKU. They have also made use of a mildly effected mouse model for PKU, BTBR-Pah enu1 [12] in conjunction with BTBR-Pah enu2 to produce BTBR-Pah enu2 / BTBR-Pah enu1 compound heterozygotes, which model mild hyperphenylalaninemia [13]. The current low-phe dietary treatment has achieved its primary goals of preventing mental retardation and providing a positive pregnancy outcome for PKU human mothers [14 16]. However, long-term compliance has proven to be very difficult. This is, in part, because of the arduous nature of the dietary regimen, requiring a major alteration in lifestyle, and because of the poor organoleptic qualities of the diet itself [17]. Dr. Sarkissian s research group has chosen to investigate PAL for enzyme substitution therapy; a form of treatment that could potentially allow PKU patients to consume a more normal diet. PAL was chosen for a number of reasons: (1) unlike Phe hydroxylase, PAL is a robust autocatalytic protein without the need for the very costly Phe hydroxylase cofactor. It is also an enzyme that stoichiometrically converts L-Phe to the harmless metabolites trans-cinnamic acid and trivial amounts of ammonia [18 20]; (2) the proposed route of protected PAL administration is oral as it will deplete the Phe pool in the intestine, whether the Phe source is dietary or from the endogenous run out of free Phe from the bound pool [21]; and (3) cloning technology (Ibex Technologies, Montreal, Canada) has enabled the production of an economical supply of PAL [22]. Dr. Sarkissian reported that her research group has been successful at reducing blood Phe levels with PAL and, in doing so, has demonstrated both the proof of pharmacological and physiological principles. First, they verified the efficacy of blood Phe abatement by intraperitoneal injection of PAL into PKU mice and showed that it acted to lower ambient blood Phe levels and that the effect persisted over 24 h. Second, they showed that PAL could be administered orally. This second result took two forms: (1) protected free PAL, enclosed within Escherichia coli cells and delivered orally, allowed free access to the enzyme while protecting PAL from the action of digestive enzymes, which were unable to penetrate the cells and (2) PAL was orally delivered with the protease inhibitor aprotinin [22]. This work has demonstrated that oral enzyme substitution therapy with PAL has significant promise for future treatment of PKU. The application of this form of therapy in humans should control the Phe pool size without drastic lifestyle restriction. Various oral protein drug strategies are currently being implemented with the aim of improving PAL protection, bioavailability, and producing a formulation that is fit for repeated administration. The meeting concluded with an extended roundtable dialog by all participants. This discussion focused largely on two areas: remaining problems that need to be solved to extend the utility of the PKU mouse model; and other areas of fruitful future research that had not been addressed elsewhere in the presentations by meeting participants. The use of current methods of dietary manipulation (i.e., feeding a Phe-deficient diet, addition of Phe to the drinking water) yields blood Phe levels that are significantly erratic, a problem that seems to arise due to the fast-release nature of the purified Phe consumed. This is an issue for several of the experimental pursuits, especially maternal PKU studies and PAL supplementation studies. The following were suggested methods for reducing these fluctuations: (1) addition of solid Phe to the defined diet during formulation (this option may ultimately require the Phe to be supplied by a complex protein source, which will be gradually broken down during digestion); (2) an implantable pump to deliver a steady dose rate over time (a more elaborate option); and (3) frequent injection or oral gavage of a Phe solution (a more invasive and labor-intensive option). One current shortcoming that can hamper learning and behavior studies is that there is presently no way to produce completely unaffected mutant animals. Such mice are typically protected by their birth mother s metabolism in utero but must nurse to survive after birth. Unfortunately, the Phe content of the nursing diet produced by a female, even on a low-phe diet, is far too high for a mutant neonate and, presumably, a significant amount of brain damage is incurred during the nursing period before the mutant animal can be weaned onto a low-phe dietary condition. More elaborate ways to solve this problem include successful perinatal implementation of a PAL-type therapy or somatic gene therapy treatment. A less elaborate option is the pup-in-a-cup protocol in which a neonate is intubated and fed a low Phe nursing diet while being incubated at mouse body temperature for a period of 2 3 weeks [23]. Acquiring PKU mice can be difficult and costly. Until recently, interested parties have been able to obtain the BTBR-Pah enu1 and BTBR-Pah enu2 mice from the Jackson Laboratory. This is, in principle, an ideal situation in
5 260 J. David McDonald et al. / Molecular Genetics and Metabolism 76 (2002) which all users obtain their animals from the same source and changes introduced by genetic drift are thereby minimized. However, the Jackson Laboratory recently decided that, due to insufficient demand, these mutant lines will be cryopreserved, an option for preservation that implies greatly increased cost and time to supply animals in the future. This decision leaves practicing PKU mouse researchers as the sole remaining inexpensive source for mutant animals. A possible solution to this quandary is to seek out new commercial sources for archiving, production, and distribution of mutant animals that all users may access quickly and easily. Finally, in addressing areas of future fruitful research we discussed gene therapeutic correction of the PKU phenotype in these mice. This disease model seems especially promising for this purpose for three reasons. It confers a decided hypopigmentation on mutant animals, which have high blood levels of Phe. Anything that reduces the blood Phe levels will increase the ability of the mutant animal to produce pigment. This yields an easily visible coat-color gauge, indicating therapeutic levels of gene expression. Further, it is clear from working with the mild BTBR-Pah enu1 strain that 5% of normal Phe hydroxylase activity is enough to reverse the mutant phenotype. Lastly, the disease PKU has a well-defined and accessible target organ, the liver. Although there have been several attempts in the past with older generation retroviral and adenoviral gene transfer systems that yielded only temporary correction of the PKU phenotype, the newer adeno-associated virus gene transfer systems seem to hold much greater promise for long-term correction. It is hoped that successful application of these vectors to this PKU model system will not only provide new treatment options for humans afflicted with PKU but, inasmuch as PKU is a paradigm of many other inborn errors of metabolism, will also provide new options for other human heritable diseases. Acknowledgments The authors are grateful to Associazione OASI Maria Santissima (Troina) for the financial support in the organization of the PKU mouse workshop. The organizers of the workshop (V. Romano and F. Calı) address special thanks to the Scientific Director (Prof. G.F. Ayala) and the President (Father L. Ferlauto) of OASI Institute for continuing encouragement and advice. References [1] S. Cho, J.D. McDonald, The effect of maternal blood phenylalanine level on mouse maternal phenylketonuria offspring, Mol. Genet. Metab. 74 (2001) [2] J.D. McDonald, C.K. Charlton, Characterization of mouse phenylalanine hydroxylase mutations and their correlation with genotype/phenotype relationships in human phenylketonuria, Genomics 39 (1997) [3] R. Koch, W. Hanley, H. Levy, R. Matalon, B. Rouse, F. Trefz, F. Guttler, C. Azen, E. Friedman, L. Platt, F. de la Cruz, Maternal phenylketonuria: an international study, Mol. Genet. Metab. 71 (2000) [4] S. Puglisi-Allegra, S. Cabib, T. Pascucci, R. Ventura, F. Calı, V. Romano, Dramatic brain aminergic deficit in a genetic model of phenylketonuria, NeuroReport 11 (2000) [5] P. Roullet, A. Mele, M. Ammassari-Teule, Ibotonic acid lesions of the nucleus accumbens improve detection of spatial novelty in poor spatial learner mice, Behav. Neurosci. 111 (1997) [6] D.G. Mumby, Perspectives on object-recognition memory following hippocampal damage: lessons from studies in rats, Behav. Brain Res. 127 (2001) [7] C.B. Smith, J. Kang, Cerebral protein synthesis in a genetic mouse model of phenylketonuria, Proc. Natl. Acad. Sci. USA 97 (2000) [8] A. Pandey, M. Mann, Proteomics to study genes and genomes, Nature 405 (2000) [9] J.M. Thornton, From genome to function, Science 292, [10] R.A. Wapnir, R.I. Hawkins, J.H. Stevenson, Ontogenesis of phenylelenine and tryptophan hydroxylation in rat brain and liver, Biol. Neonate 18 (1971) [11] U. Lichter-Konecki, C.M. Hipke, D.S. Konecki, Human phenylalanine hydroxylase gene expression in kidney and other nonhepatic tissues, Mol. Genet. Metab. 67 (1999) [12] J.D. McDonald, V.C. Bode, W.F. Dove, A. Shedlovsky, Pah hph-5 :a mouse mutant deficient in phenylalanine hydroxylase, Proc. Natl. Acad. Sci. USA 87 (1990) [13] C.N. Sarkissian, D.M. Boulais, J.D. McDonald, C.R. Scriver, A heteroallelic mouse model: a new orthologue for human hyperphenylalaninemia, Mol. Genet. Metab. 69 (2000) [14] C.R. Scriver, S. Kaufman, R. Eisensmith, S.L.C. Woo, The hyperphenylalaninemias, in: C.R. Scriver, A.L. Beadet, W.S. Sly, D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease, 7th ed., McGraw-Hill, New York, 1995, pp [15] F. Cockburn, B.E. Barwell, D.P. Brenton, J. Chapple, B. Clark, G. Curzon, D.C. Davidson, A.J. Heeley, S.C. Laing, I.A.F. Lister-Cheese, Recommendations on dietary management of phenylketonuria. Report of medical research council working party on phenylketonuria, Arch. Dis. Child. 68 (1993) [16] S.E. Waisbren, P. Chang, H.L. Levy, H. Shifrin, E. Allred, C. Azen, F. De La Cruz, W. Hanley, R. Koch, R. Matalon, B. Rouse, Neonatal neurological assessment of offspring in maternal phenylketonuria, J. Inherit. Metab. Dis. 21 (1998) [17] C.R. Scriver, S. Kaufman, Hyperphenylalaninemia: phenylalanine hydroxylase deficiency, in: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, K. Kinzler, B. Vogelstein (Eds.), The Metabolic and Molecular Bases of Inherited Disease, 8th ed., McGraw-Hill, New York, [18] J.A. Hoskins, G. Jack, H.E. Wade, R.J.D. Peiris, E.C. Wright, D.J.T. Starr, J. Stern, Enzymatic control of phenylalanine intake in phenylketonuria, Lancet 1 (1980) [19] J.A. Hoskins, J. Gray, Phenylalanine ammonia lyase in the management of phenylketonuria: relationship between ingested cinnamate and urinary hippurate in humans, Res. Commun. Chem. Pathol. Pharmacol. 35 (1982)
6 J. David McDonald et al. / Molecular Genetics and Metabolism 76 (2002) [20] J.A. Hoskins, S.B. Holliday, A.M. Greenway, The metabolism of cinnamic acid by healthy and phenylketonuria adults: a kinetic study, Biomed. Mass. Spectrom. 11 (1984) [21] T.M.S. Chang, L. Bourget, C. Lister, A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria, Artif. Cells Blood Substit. Immobil. Biotechnol. 23 (1995) [22] C.N. Sarkissian, Z. Shao, F. Blain, R. Peevers, H. Su, R. Heft, T.M.S. Chang, C.R. Scriver, A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase, Proc. Natl. Acad. Sci. USA 96 (1999) [23] J.R. West, Use of pup in a cup model to study brain development, J. Nutr. 123 (Suppl. 2) (1993)
Nutritional factors affecting serum phenylalanine concentration during pregnancy for identical twin mothers with phenylketonuria
Nutritional factors affecting serum phenylalanine concentration during pregnancy for identical twin mothers with phenylketonuria By: C. Fox, J. Marquis, D.E. Kipp This is the accepted version of the following
More informationAnnual Conference. 34th. The Rendezvous Hotel Skipton, Yorkshire. Welcome to. Programme Information & Abstracts
Welcome to 34th Annual Conference 2007 Programme Information & Abstracts The Rendezvous Hotel Skipton, Yorkshire The National Society for Phenylketonuria (United Kingdom) Ltd. NSPKU, PO Box 26642, London
More informationINVESTIGATION THE PREVALENCE OF MUTATIONS IVS 10 AND R158Q IN A NUMBER OF IRANIAN PATIENTS WITH PKU
: 293-297 ISSN: 2277 4998 INVESTIGATION THE PREVALENCE OF MUTATIONS IVS 10 AND R158Q IN A NUMBER OF IRANIAN PATIENTS WITH PKU SHIRIN JAHANBAZI, FATEMEHKESHAVARZI* Department of Biology, Sanandaj Branch,
More informationTherapeutic Programming of Synthetic Biotic Medicines
Therapeutic Programming of Synthetic Biotic Medicines Synthetic Biotic TM medicines to perform and deliver critical therapeutic functions to treat diseases throughout the body An Engineered E. coli Nissle
More informationPhenylketonuria (PKU) the Biochemical Basis. Biol 405 Molecular Medicine
Phenylketonuria (PKU) the Biochemical Basis Biol 405 Molecular Medicine PKU a history In 1934 Følling identified a clinical condition - imbecillitas phenylpyruvica. Mental retardation associated with this
More informationSummary comments: An essential pattern employed by all living things: DNA ö RNA ö Protein
Summary comments: An essential pattern employed by all living things: DNA ö RNA ö Protein DNA is the information storage molecule. RNA in an intermediate in information flow. Proteins do most of the jobs
More information1 Cognitive, Psychological and Behavioral Assessment Based Evidence
1 Cognitive, Psychological and Behavioral Assessment Based Evidence Preface Current medical evidence has led experts on PKU to suspect that current therapy for PKU may leave individuals with an increased
More informationPKU, a genetic disease, illustrating the principle:
PKU, a genetic disease, illustrating the principle: DNA RNA Protein What happens when a job doesn t get done? I. PKU, illustrates the relevance of chemistry to human health. PKU stands for phenylketonuria.
More informationDisclosure. I have no disclosures to mention
Disclosure I have no disclosures to mention Liberalization of the Dietary Restrictions for PKU Patients: Large Neutral Amino Acids (LNAA) Supplementation in PKU Mice Dr. Eddy A. van der Zee, University
More informationNIH Public Access Author Manuscript Curr Dir Psychol Sci. Author manuscript; available in PMC 2010 February 1.
NIH Public Access Author Manuscript Published in final edited form as: Curr Dir Psychol Sci. 2009 February 1; 18(1): 48 52. doi:10.1111/j.1467-8721.2009.01604.x. Phenylketonuria in Children and Mothers:
More informationChapter 1: What is PKU?
Chapter 1: What is PKU? A Parent's Perspective "If our child with PKU had been our first instead of our third, or if we had wanted more children after we had her, we would have done so, even knowing the
More informationNEUROCOGNITIVE, OUTCOMES IN PKU: IT S TIME TO RAISE THE BAR
NEUROCOGNITIVE, OUTCOMES IN : IT S TIME TO RAISE THE BAR KEY POINTS 1. High Phenylalanine (Phe) levels harm the brain.. Traditional therapies do not completely protect individuals with. 3. New approaches
More informationMerck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU Below 4 Years of Age
Your Contact News Release Gangolf Schrimpf +49 6151 72-9591 Investor Relations +49 6151 72-3321 July 20, 2015 Merck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU
More informationThe What, Why and How of Large Neutral Amino Acids
The What, Why and How of Large Neutral Amino Acids Kathryn Moseley, MS, RD Assistant Professor of Pediatrics USC/Keck School of Medicine LAC+USC Medical Center December 5 th, 2017 The opinions reflected
More informationNot intended for UK based media. Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years of age
Your Contact News Release Bettina Frank Phone +49 6151 72-4660 Not intended for UK based media Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years
More informationNew treatment options in PKU and future role of dietary treatment
New treatment options in PKU and future role of dietary treatment Michael Staudigl (physician), Katharina Dokoupil (nutritionist), Esther M. Maier (physician, head of department) Dr. von Hauner Children
More informationLarge neutral amino acids in the treatment of PKU: from theory to practice
J Inherit Metab Dis (2010) 33:671 676 DOI 10.1007/s10545-010-9216-1 ADVANCES AND CHALLENGES IN PKU Large neutral amino acids in the treatment of PKU: from theory to practice Francjan J. van Spronsen &
More informationPrerequisites Amino acid synthesis and degradation pathways. Integration of amino acid metabolic pathways with carbohydrate metabolic pathways.
Case 30 Phenylketonuria Focus concept The characteristics of phenylalanine hydroxylase, the enzyme missing in persons afflicted with the genetic disorder phenylketonuria (PKU), are examined. Prerequisites
More informationPathophysiology of the Phenylketonuria
Problem 4. Pathophysiology of the Phenylketonuria Readings for this problem are found on pages: 79-82, 84, 85-6, 945-6 and 1019 of your Pathophysiology (5 th edition) textbook. (This problem was based
More informationA. We are constantly being tested (from birth). 1) Why? Test newborns to check for congenital health problems. 2) What does congenital mean?
M 109 Introduction I. PKU illustrates the relevance of chemistry to human health Why is chemistry important in human health? Ex.: PKU (phenylketonuria) ref. Matalon, KM Top lin Nutr 16(4):41-50 (2001)
More informationNutritional Supplementation and Fetal Alcohol Spectrum Disorder
Nutritional Supplementation and Fetal Alcohol Spectrum Disorder 1,2 Anna Patten, PhD; 1,2 Brian Christie, PhD; 3 Courtney Green, PhD and 3 Jocelynn Cook, PhD MBA. 1 Division of Medical Sciences, University
More informationThe National Society for Phenylketonuria (United Kingdom) Ltd. The Child with PKU. Brenda Clark Professor Forester Cockburn Dr Linda Tyfield
The National Society for Phenylketonuria (United Kingdom) Ltd. The Child with PKU Brenda Clark Professor Forester Cockburn Dr Linda Tyfield Revised by Dr Andrew Morris Front cover illustration kindly provided
More informationFetal Growth Retardation Caused by Maternal Dietary Amino Acid Imbalance
Nutritional Adaptation of the Gastrointestinal Tract of the Newborn, edited by N. Kretchmer and A. Minkowski. Nestle, Vevey/Raven Press, New York 1983. Fetal Growth Retardation Caused by Maternal Dietary
More informationPAH phenylalanine + oxidant tyrosine CH 2 +H 3 N
M 109 Introduction An essential pattern employed by all living things: DNA RNA Protein DNA is the information storage molecule. RNA is an intermediate in information flow. Proteins do most of the jobs
More informationPKU PKU. Phenylketonuria TEMPLE. Information for families following Information for families after a positive newborn screening
PKU Phenylketonuria PKU Information for families following newborn a positive screening newborn screening Information for families after a positive newborn screening Information for families after a positive
More informationPKU, KUVAN, and You PKU treatment and support for adults and young adults
PKU, KUVAN, and You PKU treatment and support for adults and young adults An educational brochure brought to you by BioMarin Pharmaceutical Inc. Phe control it s a lifelong goal! Most young people with
More informationPhenylketonuria Jonathan Baghdadi and Evan Marlin
Phenylketonuria Jonathan Baghdadi and Evan Marlin Hyperphenylalaninemia (HPA) was first connected to certain types of mental retardation in 1934 by Asjborn Folling. Just a few years later it was understood
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 101 (2010) 110 114 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Sapropterin therapy increases
More informationAmino Acids in Dairy Nutrition Where Do They Fit?
Amino Acids in Dairy Nutrition Where Do They Fit? T. R. Overton and L. E. Chase Department of Animal Science Cornell University As our understanding of the biology underlying specifics of protein nutrition
More information- Aya Alomoush. - Talal Al-Zabin. - Belal Azab. 1 P a g e
24 - Aya Alomoush - Talal Al-Zabin - Belal Azab 1 P a g e 1) Features of autosomal dominant inheritance: A) Vertical transmission: direct transmission from grandparent to parent to child without skipping
More informationIn vitro expression analysis of R68G and R68S mutations in phenylalanine hydroxylase gene
Vol. 47 No. 2/2000 365 369 QUARTERLY In vitro expression analysis of R68G and R68S mutations in phenylalanine hydroxylase gene Cezary ekanowski 1, Belen Perez 2, Lourdes R. Desviat 2, Wojciech Wiszniewski
More informationUse of Enzyme Artificial Cells for Genetic Enzyme Defects that Increase Systemic Substrates to Toxic Levels
CHAPTER 6 Use of Enzyme Artificial Cells for Genetic Enzyme Defects that Increase Systemic Substrates to Toxic Levels 6.1. Introduction General The basic principle on the use of artificial cells containing
More informationAutism and Vitamin D. Medical Hypotheses Volume 70, Issue 4, 2008, Pages
Autism and Vitamin D 1 Medical Hypotheses Volume 70, Issue 4, 2008, Pages 750-759 John Jacob Cannell Atascadero State Hospital, Psychiatry, Atascadero, CA This study has 89 references. FROM ABSTRACT: Any
More informationTrends in Enzyme Therapy for Phenylketonuria
Trends in Enzyme Therapy for Phenylketonuria Woomi Kim, 1,2 Heidi Erlandsen, 3, * Sankar Surendran, 4 Raymond C. Stevens, 1 Alejandra Gamez, Kimberlee Michols-Matalon, Stephen K. Tyring, 5 and Reuben Matalon
More informationPhenylketonuria: variable phenotypic outcomes
284 2 Med Genet 1993; 30: 284-288 Department of Human Genetics, Sackler School of Medicine, Tel Aviv University, Ramat Aviv 69978, Israel. S Kleiman L Vanagaite J Bernstein Y Shiloh Child Development Institute,
More informationnumber Done by Corrected by Doctor
number 33 Done by Omar Sami Corrected by Waseem abu obeida Doctor Diala Too late for second guessing, too late to go back to sleep 1 P age Just try defying gravity This sheet will be divided to two parts,
More informationProteins and Amino Acids. Benjamin Caballero, MD, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationPhenylketonuria in Iranian population: a study in institutions for mentally retarded in Isfahan
Mutation Research 526 (2003) 45 52 Phenylketonuria in Iranian population: a study in institutions for mentally retarded in Isfahan Sadeq Vallian, Elham Barahimi 1, Hasan Moeini Department of Biology, Faculty
More informationChapter 7. Discussion and impact
Chapter 7 Discussion and impact 225 Affective pathology is a complex construct which encompasses a pathological disturbance in primary emotions, rapidly shifting from neutral to intense perception, associated
More informationChapter 9. Biotransformation
Chapter 9 Biotransformation Biotransformation The term biotransformation is the sum of all chemical processes of the body that modify endogenous or exogenous chemicals. Focus areas of toxicokinetics: Biotransformation
More informationAmal Alamri. Phenylketonuria
Amal Alamri Phenylketonuria Norwegian doctor Asbjørn Følling (left) discovered phenylpyrouvica (later termed phenylketonuria) in 1934 upon discovering that ten mentally retarded patients had phenylpyruvic
More informationBEHAVIORAL ASSESMENT OF THE Pah enu2 MOUSE MODEL OF PHENYLKETONURIA PADMINI ASHOK KUMAR
BEHAVIORAL ASSESMENT OF THE Pah enu2 MOUSE MODEL OF PHENYLKETONURIA By PADMINI ASHOK KUMAR A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
More informationArtificial liver in PKU. Donna Santillan, PhD University of Iowa Hospitals & Clinics Department of Obstetrics & Gynecology
Artificial liver in PKU Donna Santillan, PhD University of Iowa Hospitals & Clinics Department of Obstetrics & Gynecology Discovery of PKU Discovery of PKU Discovered in 1934 by Dr. Asbjörn Fölling Egeland
More informationAMERICAN ACADEMY OF PEDIATRICS. New Developments in Hyperphenylalaninemia. Committee on Nutrition
AMERICAN ACADEMY OF PEDIATRICS Committee on Nutrition New Developments in Hyperphenylalaninemia In recent years it has become apparent that hyperphenylalaninemia in newborn infants may be caused by a variety
More informationAn introduction to Phenylketonuria (PKU)
An introduction to Phenylketonuria (PKU) What is PKU? Phenylketonuria (sounds like feen-il-ke-ton-u-re-ah) or PKU for short PKU is a manageable condition which affects the way the body uses protein. Children
More informationCommittee Approval Date: August 15, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru152 Topic: Kuvan, sapropterin Date of Origin: March 18, 2008 Committee Approval Date: August 15, 2014 Next Review Date: September 2015 Effective Date: October 1,
More informationPhenylketonuria and Its Variants
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 7, No. 2 Copyright 1977, Institute for Clinical Science Phenylketonuria and Its Variants SEYMOUR KAUFMAN, Ph.D. and SHELDON MILSTIEN Ph.D. Laboratory of
More informationClasses of Neurotransmitters. Neurotransmitters
1 Drugs Outline 2 Neurotransmitters Agonists and Antagonists Cocaine & other dopamine agonists Alcohol & its effects / Marijuana & its effects Synthetic & Designer Drugs: Ecstasy 1 Classes of Neurotransmitters
More informationThe Key to Understanding Autism: The Latest in Brain Development and Information Processing
WORKSHOP G-6 The Key to Understanding Autism: The Latest in Brain Development and Information Processing Daily Behavioral Health and Building Behaviors Autism Center Suggested Audience: Adult Service Provider,
More informationScreening for Phenylketonuria: A Literature Update for the U.S. Preventive Services Task Force
Screening for Phenylketonuria: A Literature Update for the U.S. Preventive Services Task Force Prepared by: Iris Mabry-Hernandez, MD, MPH Tracy Wolff, MD, MPH Kathy Green, MD, MPH Corresponding Author:
More informationHuman inherited diseases
Human inherited diseases A genetic disorder that is caused by abnormality in an individual's DNA. Abnormalities can range from small mutation in a single gene to the addition or subtraction of a whole
More informationEFFECTS OF REPLACING WHEY PROTEIN CONCENTRATE WITH CRYSTALLINE AMINO ACIDS ON WEANLING PIG PERFORMANCE
EFFECTS OF REPLACING WHEY PROTEIN CONCENTRATE WITH CRYSTALLINE AMINO ACIDS ON WEANLING PIG PERFORMANCE 1999 Animal Science Research Report Authors: Story in Brief Pages 258-265 J. Chung, S.D. Carter,C.V.
More informationClinical Commissioning Policy: Sapropterin (Kuvan ) For Phenylketonuria: Use In Pregnancy. December Reference : NHSCB/E6/a
Clinical Commissioning Policy: Sapropterin (Kuvan ) For Phenylketonuria: Use In Pregnancy December 2012 Reference : NHSCB/E6/a NHS Commissioning Board Clinical Commissioning Policy: Sapropterin (Kuvan
More informationAMINO ACID DRINK WHAT ARE AMINO ACIDS?
Executive Summary AMINO ACID DRINK WHAT ARE AMINO ACIDS? Human body is 60 percent water and 20 percent protein. Protein plays a crucial role in almost all biological processes and amino acids are the building
More informationPhenylketonuria (PKU) is an inherited disease of Phe metabolism
Cerebral protein synthesis in a genetic mouse model of phenylketonuria Carolyn Beebe Smith* and Julia Kang Laboratory of Cerebral Metabolism, National Institute of Mental Health, United States Public Health
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): Overall, this is an interesting study. The authors used a custom microfluidic device to deliver precise concentrations of bacterial food to worms
More informationMaternal Infection and Autism
Maternal Infection and Autism Kristen Wierda Jackie Luu Nicole Chang Larysa Santavy October 17, 2017 Outline - What is autism? - Analyzing maternal infection - Model of Maternal Immune Activation (MIA)
More informationJAI La Leche League Epigenetics and Breastfeeding: The Longterm Impact of Breastmilk on Health Disclosure Why am I interested in epigenetics?
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 JAI La Leche League Epigenetics and Breastfeeding: The Longterm Impact of Breastmilk on Health By Laurel Wilson, IBCLC, CLE, CCCE, CLD Author of The Greatest Pregnancy
More informationEffect of Excess of Individual Essential Amino Acids in Diets on Chicks
135 Effect of Excess of Individual Essential Amino Acids in Diets on Chicks Jun-ichi OKUMURA and Kiyoto YAMAGUCHI Laboratory of Animal Nutrition, Faculty of Agriculture, Nagoya University, Nagoya-shi 464
More informationKin recognition plays multiple roles across the animal kingdom. From an
Sample paper critique #1 Kin recognition plays multiple roles across the animal kingdom. From an evolutionary point of view, one might expect kin recognition to be particularly important in the recognition
More informationRecent Studies of Phenylketonuria By: Jennifer Gastelum Dr. Koni Stone Copyright 2014
Recent Studies of Phenylketonuria By: Jennifer Gastelum Dr. Koni Stone Copyright 2014 Phenylketonuria (PKU) is an autosomal recessive genetic disorder that causes an accumulation of toxic metabolites in
More informationGenetics Unit Exam. Number of progeny with following phenotype Experiment Red White #1: Fish 2 (red) with Fish 3 (red) 100 0
Genetics Unit Exam Question You are working with an ornamental fish that shows two color phenotypes, red or white. The color is controlled by a single gene. These fish are hermaphrodites meaning they can
More informationTEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP. British Inherited Metabolic Diseases Group
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP British Inherited Metabolic Diseases Group BASED ON THE ORIGINAL TEMPLE WRITTEN BY BURGARD AND WENDEL PKU Information for
More informationSummary. Syndromic versus Etiologic. Definitions. Why does it matter? ASD=autism
Summary It is becoming clear that multiple genes with complex interactions underlie autism spectrum (ASD). A small subset of people with ASD, however, actually suffer from rare single-gene Important to
More informationPKU TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ DESIGNED AND ADAPTED BY THE DIETITIANS GROUP
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ Australasian Society for Inborn Errors of Metabolism DESIGNED AND ADAPTED BY THE DIETITIANS GROUP PKU British
More informationCASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?
CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.
More informationProtein Recommendations: Time for an Update?
Protein Recommendations: Time for an Update? Rajavel Elango Ph.D. Assistant Professor Department of Pediatrics, School of Population and Public Health University of British Columbia Scientist Level 1 Nutrition
More informationAJINOMOTO EUROLYSINE INFORMATION
AJINOMOTO ANIMAL NUTRITION AJINOMOTO EUROLYSINE INFORMATION L-Tryptophan supplementation to enhance piglet growth N 23 T ryptophan, like lysine, threonine and methionine is an essential amino acid. It
More informationMammary Gland Metabolism of Amino Acids in the Lactating Sow: An In Vitro Study
Mammary Gland Metabolism of Amino Acids in the Lactating Sow: An In Vitro Study Walter L. Hurley, Professor, and Jane M. Bryson, Research Associate Department of Animal Sciences, University of Illinois,
More information44. Screening for Phenylketonuria
44. Screening for Phenylketonuria Burden of Suffering PKU is an inborn error of phenylalanine metabolism that occurs in 1 of every 12,000 births in North America. 1,2 In the absence of treatment during
More information7 Medical Genetics. Hemoglobinopathies. Hemoglobinopathies. Protein and Gene Structure. and Biochemical Genetics
SESSION 7 Medical Genetics Hemoglobinopathies and Biochemical Genetics J a v a d F a s a J a m s h i d i U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 Hemoglobinopathies
More informationPKU, KUVAN, and Your Child Making smart choices for PKU treatment
PKU, KUVAN, and Your Child Making smart choices for PKU treatment An educational brochure brought to you by BioMarin Pharmaceutical Inc. + = Low Low- diet Indication KUVAN (sapropterin dihydrochloride)
More informationDoctor of Philosophy
Regulation of Gene Expression of the 25-Hydroxyvitamin D la-hydroxylase (CYP27BI) Promoter: Study of A Transgenic Mouse Model Ivanka Hendrix School of Molecular and Biomedical Science The University of
More informationCongenital CMV infection. Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara
Congenital CMV infection Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara Congenital CMV infection Approximately 0.15 2% of live births
More informationAsingle inherited mutant gene may be enough to
396 Cancer Inheritance STEVEN A. FRANK Asingle inherited mutant gene may be enough to cause a very high cancer risk. Single-mutation cases have provided much insight into the genetic basis of carcinogenesis,
More informationProblem Set 5 KEY
2006 7.012 Problem Set 5 KEY ** Due before 5 PM on THURSDAY, November 9, 2006. ** Turn answers in to the box outside of 68-120. PLEASE WRITE YOUR ANSWERS ON THIS PRINTOUT. 1. You are studying the development
More informationThe Amino Acid Content of Hen's Egg in Relation to Dietary Protein Intake, Breed and Environment 1
The Amino Acid Content of Hen's Egg in Relation to Dietary Protein Intake, Breed and Environment 1 P. Lunven and C. Le Clément de St. Marcq Protein Food Development Group Nutrition Division In 1963 the
More informationREAD THIS FIRST. Your Name
Introduction to Biochemistry Final Examination - Individual (Part I) Monday, 24 May 2010 7:00 8:45 PM H. B. White Instructor 120 Points Your Name "Ability is what you're capable of doing. Motivation determines
More informationFood and Beverages Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran b
Mædica - a Journal of Clinical Medicine MAEDICA a Journal of Clinical Medicine 2015; 10(4): 310-314 ORIGINAL PAPERS Frequency of the VNTR-Polymorphisms at the PAH Gene in the Iranian Azeri Turkish Patients
More informationRetinoic Acid & Experimental Design Laboratory
Name: Date: Retinoic Acid & Experimental Design Laboratory Motivation Vitamin A deficiency claims the lives of over 600,000 children under the age of 5 annually 1. Maternal vitamin A deficiency leads to
More informationIntroduction to Organic Acidemias. Hilary Vernon, MD PhD Assistant Professor of Genetic Medicine Johns Hopkins University 7.25.
Introduction to Organic Acidemias Hilary Vernon, MD PhD Assistant Professor of Genetic Medicine Johns Hopkins University 7.25.2014 A Brief Historical Overview Garrod, Archibald E. 1902. The Incidence of
More informationComplex Traits Activity INSTRUCTION MANUAL. ANT 2110 Introduction to Physical Anthropology Professor Julie J. Lesnik
Complex Traits Activity INSTRUCTION MANUAL ANT 2110 Introduction to Physical Anthropology Professor Julie J. Lesnik Introduction Human variation is complex. The simplest form of variation in a population
More informationGenetic Counselors role in maternal PKU: Patient and Genetic Counselor perspectives. Master s Thesis. Presented to
Genetic Counselors role in maternal PKU: Patient and Genetic Counselor perspectives Master s Thesis Presented to The Faculty of the Graduate School of Arts and Sciences Brandeis University Department of
More informationMetabolic Disorders. Chapter Thomson - Wadsworth
Metabolic Disorders Chapter 28 1 Metabolic Disorders Inborn errors of metabolism group of diseases that affect a wide variety of metabolic processes; defective processing or transport of amino acids, fatty
More informationAmino Acid Oxidation and the Urea Cycle
Amino Acid Oxidation and the Urea Cycle Amino Acids: Final class of biomolecules whose oxidation contributes significantly to the generation of energy Undergo oxidation in three metabolic circumstances
More informationEpigenetics 101. Kevin Sweet, MS, CGC Division of Human Genetics
Epigenetics 101 Kevin Sweet, MS, CGC Division of Human Genetics Learning Objectives 1. Evaluate the genetic code and the role epigenetic modification plays in common complex disease 2. Evaluate the effects
More informationSolutions to Genetics Unit Exam
Solutions to Genetics Unit Exam Question 1 You are working with an ornamental fish that shows two color phenotypes, red or white. The color is controlled by a single gene. These fish are hermaphrodites
More informationConversion of amino acids الفريق الطبي األكاديمي
الفريق الطبي األكاديمي لكية الطب البرشي البلقاء التطبيقية / املركز 2022 2016/ -the ones with * are the essential amino acids- - Histidine decarboxylation -> histamine Page 1 - Glutamine is a nitrogen carrier
More informationM1 - Renal, Fall 2007
University of Michigan Deep Blue deepblue.lib.umich.edu 2007-09 M1 - Renal, Fall 2007 Lyons, R.; Burney, R. Lyons, R., Burney, R. (2008, August 07). Renal. Retrieved from Open.Michigan - Educational Resources
More information2015 PKU Patient Survey Results. National PKU Alliance PO Box 501, Tomahawk, WI
2015 PKU Patient Survey Results National PKU Alliance PO Box 501, Tomahawk, WI 54487 www.npkua.org www.adultswithpku.org The NPKUA Patient Survey demonstrates that strict dietary therapy and treatment
More informationEFFECTS OF AMINO ACID SUBSTITUTIONS FOR WHEY PROTEIN CONCENTRATE ON WEANLING PIG PERFORMANCE. Authors: J. Chung, S.D. Carter and J.C.
EFFECTS OF AMINO ACID SUBSTITUTIONS FOR WHEY PROTEIN CONCENTRATE ON WEANLING PIG PERFORMANCE 1999 Animal Science Research Report Authors: Story in Brief Pages 266-272 J. Chung, S.D. Carter and J.C. Whisenhunt
More informationBiol212 Biochemistry of Disease Neurological Disorders: Prions
Biol212 Biochemistry of Disease Neurological Disorders: Prions Prions Transmissible spongiform encephalopathies (TSEs) are diseases of the central nervous system caused by unconventional infectious agents,
More informationPHENYLKETONURIA. Debbie Galo
PHENYLKETONURIA Debbie Galo What it is PKU? 1934 Metabolic disorder (chromosome 12) Autosomal recessive Deficiency of enzyme Phenylalanine Hydroxylase (PAH) Cannot convert phenylalanine to tyrosine More
More informationMCB140: Second Midterm Spring 2010
MCB140: Second Midterm Spring 2010 Before you start, print your name and student identification number (S.I.D) at the top of each page. There are 11 pages including this page. You will have 150 minutes
More informationAnalysis of Neurotransmitters. Simon Heales
Analysis of Neurotransmitters Simon Heales HealeS@gosh.nhs.uk Tyrosine O 2 L-Dopa Dopamine HVA Tryptophan 5-HTP PLP Serotonin 5-HIAA Phenylalanine Tyrosine BH4 qbh2 BH2 CSF Sample Requirements Tube 1 Tube
More informationMULTIPLE CHOICE QUESTIONS
SHORT ANSWER QUESTIONS-Please type your awesome answers on a separate sheet of paper. 1. What is an X-linked inheritance pattern? Use a specific example to explain the role of the father and mother in
More informationUnit 3: DNA and Genetics Module 9: Human Genetics
Unit 3: DNA and Genetics Module 9: Human Genetics NC Essential Standard: 3.2 Understand how the environment, and /or the interaction of alleles, influences the expression of genetic traits. 3.3.3 Evaluate
More informationSoy Protein. Muscle health benefits: for Sports Nutrition Recovery and during aging. May 9, Mark Cope, PhD
Soy Protein Muscle health benefits: for Sports Nutrition Recovery and during aging May 9, 2017 Mark Cope, PhD Blending Proteins to Provide Better Muscle Health Importance of Muscle Health The Benefits
More informationSTEM CELL RESEARCH: MEDICAL PROGRESS WITH RESPONSIBILITY
STEM CELL RESEARCH: MEDICAL PROGRESS WITH RESPONSIBILITY A REPORT FROM THE CHIEF MEDICAL OFFICER S EXPERT GROUP REVIEWING THE POTENTIAL OF DEVELOPMENTS IN STEM CELL RESEARCH AND CELL NUCLEAR REPLACEMENT
More information